Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Application based on results from the TROPION-Breast01 Phase III trial
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
Subscribe To Our Newsletter & Stay Updated
